A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients

  • End date
    Sep 1, 2024
  • participants needed
  • sponsor
    Enlivex Therapeutics Ltd.
Updated on 7 October 2022
flank pain
inflammatory response
organ failure
septic shock
urinary urgency
leukocyte esterase


A Phase 2, Multi-Center, Randomized, Placebo-Controlled, Dose-Finding Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients


Allocetra-OTS is an immunomodulatory cell-based therapy consisting of allogeneic peripheral blood mononuclear cells that have been modified to be engulfed by macrophages and reprogram them into their homeostatic state.

This is a multi-center, randomized, placebo-controlled, dose-finding study comparing the efficacy, safety and tolerability of different dosing regimens of Allocetra-OTS, in patients with sepsis. The study aims to compare the safety and efficacy of different doses and regimens of Allocetra-OTS, as well as the clinical manifestations following Allocetra-OTS treatment, to that of Placebo in the treatment of organ failure in adult sepsis patients.

Condition Sepsis, Community-acquired Pneumonia, Urinary Tract Infections, Cholecystitis, Acute, Cholangitis Acute, Intraabdominal Infections
Treatment Placebo, Allocetra-OTS
Clinical Study IdentifierNCT04612413
SponsorEnlivex Therapeutics Ltd.
Last Modified on7 October 2022


Yes No Not Sure

Inclusion Criteria

Male or female ≥18 years and ≤90 years of age
Meets Sepsis 3 criteria
Sepsis due to infection in at least one of the below organs
1. Community-Acquired Pneumonia (CAP). 3.2. Urinary tract infection 3.3
Acute cholecystitis diagnosed by Tokyo criteria 3.4. Acute cholangitis
diagnosed by Tokyo criteria 3.5. Other intra-abdominal infections (IAI)
Adequate source control

Exclusion Criteria

Patients with acute pancreatitis
On chronic dialysis
SOFA score ≥ 10 at screening
Patients with nosocomial infection
A known malignancy
Known active symptomatic SARS-CoV-2 or chronic viral infections, such as HBV or HCV, HIV or other chronic infections
Chronic respiratory disease
Known active upper GI tract ulceration or hepatic dysfunction
Known NYHA class IV heart failure or unstable angina, ventricular arrhythmias, acute coronary disease or myocardial infarction
Known immunocompromised state or medications known to be immunosuppressive
Organ allograft or previous history of stem cell transplantation
Invasive ventilated patient and PaO2/FiO2 < 100 mmHg
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note